Bing

Significant strength was also visible among biotechnology stocks, as reflected by the 3.6% gain posted by the NYSE Arca Biotechnology Index. Alkermes (ALKS), United Therapeutics (UTHR) and Incyte (INCY) posted standout gains. Trucking, software ...
Morningstar · 18 hours ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD) acquired on Monday privately-held, late-stage rare disease drug maker Scioderm, for an upfront cash-and-stock payment of $229 million ... by United Therapeutics …
bidnessetc.com · 8/31/2015
United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 2,211 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $155.47, for a total transaction of $343,744.17. Following the …
wkrb13.com · 8/28/2015
United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 2,211 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $167.13, for a total value of $369,524.43. Following the sale, the chief ...
Watch List News · 8/22/2015
This continues the recent downtrend for UTHR, as the stock is now down nearly 10.9% in the past one-month time frame. This slump shouldn’t be too much of a surprise to investors, as the company has seen one negative revision in the past few weeks …
Yahoo Finance · 6/16/2014
United Therapeutics Corporation (Nasdaq: UTHR) announced that its Board has approved and declared a stock split. The stock split will be effected in the form of a stock dividend, in which one share of United Therapeutics common stock will be distributed ...
StreetInsider · 9/1/2009
This would appear to signify that the stock in its view is no longer cheap. Summary: UTHR is a financially-strong, free cash flow-positive biotech company focused on an important orphan disease, with an evolving focus in oncology. It is trading at a market ...
Seeking Alpha · 7/30/2013
This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible underperform ... and United Therapeutics (NASDAQ:UTHR) ranks third with a loss of 2.63%. Inovio Biomedical (AMEX:INO) follows with a loss ...
Financial News Network Online · ByPeter Chu · 7/31/2015
Analyst Raj Mehra of Auriga USA maintains his "buy" rating on United Therapeutics (NASDAQ: UTHR), while raising his estimates for the company. The target price for UTHR has been raised from $54 to $70. According to Auriga USA, United …
Benzinga · ByMonica Gerson · 1/13/2010
The negative recommendation gained significant attention considering UTHR's stock was up 50% over the prior six months, and 12 of the 15 analysts on the Street that cover the stock rated the shares a Buy. Jason's Sell call is one of only two negative ...
ZACKS · 11/17/2008
Related Searches